David Shaw’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

David Shaw’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-35,775	Closed	-$52K	–	3743
2016 Q1	$52K	Buy	35,775 +14,780	+70%	+$29.2K	﹤0.01%	3333
2015 Q4	$67K	Sell	20,995 -62,481	-75%	-$300K	﹤0.01%	3707
2015 Q3	$522K	Buy	83,476 +14,978	+22%	+$140K	﹤0.01%	3033
2015 Q2	$680K	Buy	68,498 +55,392	+423%	+$485K	﹤0.01%	2973
2015 Q1	$97K	Sell	13,106 -1,566	-11%	-$10.5K	﹤0.01%	3528
2014 Q4	$78K	Sell	14,672 -11,053	-43%	-$56.6K	﹤0.01%	3921
2014 Q3	$129K	Sell	25,725 -115,672	-82%	-$711K	﹤0.01%	3956
2014 Q2	$949K	Buy	+141,397	New	+$900K	﹤0.01%	2992

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

David Shaw's NWBO Position: Q2 2016 in Review

David Shaw sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 35,775 shares — an estimated $52K sold.

David Shaw first reported a position in NWBO in Q2 2014 and held it in 8 quarters. The position peaked at $949K in Q2 2014. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

David Shaw reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
David Shaw sold 35,775 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $52K.
David Shaw first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2014 and held it in 8 quarters.
David Shaw's Northwest Biotherapeutics, Inc. Common stock position peaked at $949K in Q2 2014.
64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on D.E. Shaw & Co's 13F filing for Q2 2016, filed 15 Aug 2016.